Lisa Pedersen v. Bio-Medical Applications

775 F.3d 1049, 39 I.E.R. Cas. (BNA) 973, 2015 U.S. App. LEXIS 90, 2015 WL 64382
CourtCourt of Appeals for the Eighth Circuit
DecidedJanuary 6, 2015
Docket14-1284
StatusPublished
Cited by57 cases

This text of 775 F.3d 1049 (Lisa Pedersen v. Bio-Medical Applications) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eighth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Lisa Pedersen v. Bio-Medical Applications, 775 F.3d 1049, 39 I.E.R. Cas. (BNA) 973, 2015 U.S. App. LEXIS 90, 2015 WL 64382 (8th Cir. 2015).

Opinion

BYE, Circuit Judge.

Lisa Pedersen sued Bio-Medical Applications of Minnesota (BMA) under the Minnesota Whistleblower Act (MWA), Minnesota Statute § 181.932, alleging BMA took adverse employment actions against her after she reported the mishandling of blood samples and a cover-up by management. The district court 1 granted Bio-Medical’s motion for summary judgment, concluding Pedersen failed to establish a prima facie case under the MWA. Pedersen appeals, and we affirm.

I

Pedersen began working for BMA, which operates dialysis climes throughout Minnesota for individuals suffering from end stage renal disease, in 2007. After becoming a registered nurse, Pedersen could assess patients, work with physicians, and administer medication to patients. BMA does not employ its own team of physicians but contracts with physician groups for patient services at its clinics.

Part of BMA’s treatment regimen for its patients involves monitoring certain components of patients’ blood, which is assessed by drawing and analyzing blood samples from patients, and then administering medications based on the results. BMA draws patients’ blood at their facilities and then sends the samples to an independent laboratory, Spectra Laboratories, Inc. (Spectra), for analysis. Spectra provides shipping instructions for the blood samples, including the size of box to use and the number of ice packages to include to keep the blood samples below a certain temperature. On the morning of April 12, 2012, when Pedersen reported to work, she learned a box of blood samples had been left in the clinic’s front lobby overnight, packed with ice packages but in the wrong type of shipping box. Another employee, a patient care technician, had discovered the blood samples prior to Ped-ersen arriving at the clinic, touched the vials to ensure the samples were still cool, repackaged them in the correct package, and sent them to Spectra.

Because the blood samples had been incorrectly packaged, Pedersen believed the samples may have been compromised. After Spectra processed the samples and returned the results to BMA, however, a registered nurse reviewed the results and determined none of the samples were abnormal. This nurse reported the results to Joelle Ince, the clinic manager, who was responsible for day-to-day operations of the clinic. Ince learned the blood samples had been packaged incorrectly the previous day when she spoke with the patient care technician who originally discovered the blood samples. Pedersen did not make a report about the blood samples to Ince. When Ince became aware of the incident, she notified her area manager, Cel-estine Kienzle, who had broad oversight responsibilities with respect to staffing issues at the clinics. Kienzle directed Ince to call the laboratory and schedule educational sessions for employees about proper packaging.

On the morning of April 17, 2012, Ince met with Pedersen to discuss concerns *1052 Ince had about Pedersen’s aggression and some performance issues, including Peder-sen failing to “close out the day” on April 12, 2012, leaving one patient without a post-weight assessment; Pedersen entering Ince’s office agitated and pointing her finger at Ince, saying with an aggressive posture Ince needed to talk with other staff; Pedersen failing to “sign off” on three medications when another nurse took over for Pedersen; and Pedersen failing to complete patient care plans. Ince informed Pedersen she would be transferred to a separate clinic with a more experienced staff. Pedersen became very upset after hearing this information and yelled at Ince, suggesting she call her area manager.

Later that day, Ince and Pedersen had a meeting with one of BMA’s contract ne-phrologists to discuss patient care planning. While discussing laboratory results, Pedersen informed the nephrologist about the blood samples left in the lobby overnight. Ince then informed the nephrologist a registered nurse at BMA reviewed the results of the blood samples and did not find any abnormalities. According to Pedersen, Ince told Pedersen not to discuss the incident with the nephrologist. After hearing the information, the nephrol-ogist did not order a redraw of any patients who had incorrectly packaged blood samples.

Following the patient care planning meeting, Pedersen contacted Kienzle to report the incident about the blood samples. Kienzle assured Pedersen they would investigate the incident and if any blood samples needed to be redrawn, then BMA would do so. Pedersen indicated to Kien-zle she believed the physicians and the medical director should be notified of the incident. Kienzle responded Pedersen should not tell the physicians about the incident because they would take care of the employee issues at the clinic.

Pedersen also reported the incident to several others, including a customer service representative at Spectra; BMA’s employee line; Kelly Tarlton, a BMA regional vice president; and Martha D’Sanchez, a BMA employee relations manager. During these conversations, Pedersen reported not only the incident, but also that she feared retaliation from management as a result of exposing questionable staff practices and a cover-up by management. Both Tarlton and D’Sanchez contacted Kienzle about Pedersen’s report. Kienzle informed them they had investigated the incident and none of the blood samples were affected. Pedersen believes the laboratory results were used to administer patient medications without first informing the patients of the incorrectly packaged blood samples.

On April 19, 2012, a patient reported to a patient care technician, who in turn reported to Kienzle, Pedersen had slapped her arm during her previous two treatments. BMA also received complaints Pedersen had impersonated Jennifer Bard, a clinic manager, on April 2, 2012, and on April 18, 2012; she inappropriately documented a patient’s treatment and failed to notify the physician as required; and she failed to obtain proper doctor’s orders for the treatment of a patient. As BMA investigated these performance issues, Pedersen went on medical leave from April 19, 2012, until May 28, 2012. While Pedersen was on leave, Kienzle asked Bard numerous times if there was a way to “get rid of’ Pedersen and suggested a number of reasons she could use to justify Pedersen’s discharge. On May 29, 2012, Kienzle and Bard met with Pedersen to discuss her performance and their concerns. Pedersen offered explanations for all of the occurrences, but Kienzle sus *1053 pended Pedersen for three days pending further investigation.

Following BMA’s investigation, BMA determined Pedersen could return to work under a corrective action plan, which included requiring Pedersen to refrain from misrepresenting herself, to exhibit respectful and professional behavior, and to appropriately document all actions with patients, obtain orders as required, and communicate with physicians. Pedersen, however, did not return to work. By the end of June 2012, BMA continued to offer Pedersen employment but as a patient care technician rather than a registered nurse due to Pedersen’s length of absence and the issuance of new nursing policies and procedures during the absence. Bard indicated to Pedersen, however, she would be retrained to her registered nurse position. Pedersen continued to refuse to return to work unless certain conditions were met by BMA.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
775 F.3d 1049, 39 I.E.R. Cas. (BNA) 973, 2015 U.S. App. LEXIS 90, 2015 WL 64382, Counsel Stack Legal Research, https://law.counselstack.com/opinion/lisa-pedersen-v-bio-medical-applications-ca8-2015.